PDCD1 and neoplasm: In healthy subjects, PD-1 triggering by the cognate ligand PD-L1 protects against autoimmune-related events, whereas in the tumor context, triggering PD-L1 is detrimental because it causes deactivation/inhibition of the T-cell response.